GEN ID Nearing Completion of Proprietary Software For DNA Testing
FONTANA, Calif., Dec 02, 2005 (BUSINESS WIRE) --
GEN ID Lab Services Inc. (GEN ID) (Pink Sheets:GDLB) announced today that it is nearing completion of its proprietary software that is designed to analyze DNA test results.
After months of testing, GEN ID is preparing to unveil to the medical community its proprietary software, which specializes in the expedited Single Nucleotide Polymorphism ("SNP") analysis. The results of SNP analysis provide physicians with a more enlightened choice of drugs. Doctors will be able to more accurately predict the effectiveness of the drugs for individual patients. The use of an SNP test to help treat childhood leukemia is currently being used by doctors and hospitals in the United States.
The GEN ID software will be the first of its kind to provide not only a complete breakdown of the genetic DNA of an individual, but it will also be able to analyze the potential effectiveness of a protocol of drug treatment programs. GEN ID's software will be a milestone in the field of Pharmacogenomics Analysis.
Pharmacogenomics examines how an individual's genetic makeup is affected by various drugs. Researchers in the field have been working to apply human genome knowledge to pharmaceuticals by identifying genes, which account for varying drug reactions in different people. The GEN ID software will help doctors, and other health care providers, customize drug therapies for individual patients.
"We believe that this software will provide doctors and hospitals an inexpensive and nearly 100% accurate method of analyzing the DNA of an individual. A recent study published in the Journal of the American Medical Association reported that adverse drug reactions accounted for more than 2.2 million serious cases, and over one hundred thousand deaths, making adverse drug reactions one of the leading causes of hospitalization and deaths in the United States," stated Dr. Steve Slilaty, GEN ID's head of medical research, and a pioneer in the field of gene therapy. "Through the use of the GEN ID software, an exact medical program can be tailored to an individual's needs, thereby eliminating the potential risk of adverse and allergic reactions, which have been the greatest cause for setbacks in hospitalization care in the past. Until now, the method most doctors use to treat serious disease is a trial and error approach, which frequently has devastating results."
Conducting DNA analyses through the GEN ID system will take the guess work out of prescribing difficult medical protocol for individuals. The program's application will result in saving lives, and millions of dollars in unnecessary treatment and subsequent damage control.
GEN ID intends to market its proprietary software to doctors and hospitals, and to make genetic testing available, eventually, to individuals. The intended result is that appropriate medical treatments will be dispensed far more accurately, and for less money. Individual patients will be able to have their entire genetic makeup downloaded to a CD Rom disk, which can then be provided to a doctor in order to assist in developing the appropriate treatment protocol.
Hector Veron, President and CEO of GEN ID, stated, "GEN ID is pleased to be in the forefront of DNA analysis in a way that benefits the medical community, especially doctors, and health care providers. GEN ID will also benefit the insurance companies by keeping costs down from misdiagnosis, and subsequent remedial treatment."
Mr. Veron continued, "The pharmaceutical industry will be in a position to develop higher quality drugs, in a shorter period of time, at a fraction of the cost. The greatest recognizable benefit of our proprietary software will be felt by the public at large. Medications will be far more customized than ever before, and the cost of health care could drop significantly."
About GEN ID:
GEN ID is in the business of providing SNP testing. SNP stands for Single Nucleotide Polymorphism. A SNP is a small genetic change, or variation, that can occur within a person's DNA sequence. This analysis will provide information on genetic predisposition to varies diseases, such as different forms of cancer, cardiovascular abnormalities, dermatological deceases, etc. SNP data also allows predicting pharmacodynamic pattern pertinent to individual drugs for individual patients.
For more information visit the company's website: www.Gen-IDLabs.com.
This news release may include "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact included or incorporated herein may constitute forward-looking statements. Although Gen-ID Lab Services believes that the forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. The forward-looking statements involve risks and uncertainties that may affect Gen-ID Lab Service's operations and financial performance. Among the factors that could cause results to differ materially are those risks discussed in Gen-ID Lab Service's filings with the Securities and Exchange Commission, including our Annual Reports on Form 10-KSB.
SOURCE: GEN ID Lab Services Inc.
GEN ID Lab Services Inc. Hector Veron, 909-574-6470 (Public Relations) or Alex, 909-609-4571 (IR Manager)
Copyright Business Wire 2005
